4.3 Article

Duality of effect of La3+ on mitochondrial permeability transition pore depending on the concentration

期刊

BIOMETALS
卷 22, 期 6, 页码 917-926

出版社

SPRINGER
DOI: 10.1007/s10534-009-9244-1

关键词

Lanthanum ion; Mitochondria; Calcium ion; Permeability transition pore

资金

  1. National Natural Science Foundation of China [20637010, 20671008]

向作者/读者索取更多资源

In order to explore the role of mitochondria in proliferation promotion and/or apoptosis induction of lanthanum, the mutual influences between La3+ and Ca2+ on mitochondrial permeability transition pore (PTP) opening were investigated with isolated mitochondria from rat liver. The experimental results revealed that La3+ influence the state of mitochondria in a concentration-dependent biphasic manner. La3+ in nanomolar concentrations, acting as a Ca2+ analog, entered mitochondrial matrix via the RuR sensitive Ca2+ channel and elevated ROS level, leading to opening of PTP indicated by mitochondrial swelling, reduction of Delta I-m and cytochrome c release. Inhibition of PTP with 10 mu M CsA attenuated the effects of La3+. However, micromolar concentrations La3+ acted mainly as a Ca2+ antagonist, inhibiting PTP opening induced by Ca2+. We postulated that this action of La3+ on mitochondria through interaction with Ca2+ might be involved in the proliferation-promoting and apoptosis induction by La3+.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Hematology

Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

Ta-Ming Liu, Jennifer A. Woyach, Yiming Zhong, Arletta Lozanski, Gerard Lozanski, Shuai Dong, Ethan Strattan, Amy Lehman, Xiaoli Zhang, Jeffrey A. Jones, Joseph Flynn, Leslie A. Andritsos, Kami Maddocks, Samantha M. Jaglowski, Kristie A. Blum, John C. Byrd, Jason A. Dubovsky, Amy J. Johnson

Article Biochemistry & Molecular Biology

Targeting Interleukin-2-inducible T-cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694

Yiming Zhong, Shuai Dong, Ethan Strattan, Li Ren, Jonathan P. Butchar, Kelsey Thornton, Anjali Mishra, Pierluigi Porcu, J. Michael Bradshaw, Angelina Bisconte, Timothy D. Owens, Erik Verner, Ken A. Brameld, Jens Oliver Funk, Ronald J. Hill, Amy J. Johnson, Jason A. Dubovsky

JOURNAL OF BIOLOGICAL CHEMISTRY (2015)

Meeting Abstract Oncology

Pharmacologic inhibition with IPI-145 and genetic inhibition of PI3K p110δ antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia

Amy J. Johnson, Shuai Dong, Daphne Guinn, Jason A. Dubovsky, Yiming Zhong, Amy Lehman, Jeff Kutok, Jennifer A. Woyach, John C. Byrd

MOLECULAR CANCER THERAPEUTICS (2015)

Editorial Material Oncology

A New Role for Lyn in the CLL Microenvironment

Shuai Dong, John C. Byrd

CANCER CELL (2016)

Article Hematology

IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells

Shuai Dong, Daphne Guinn, Jason A. Dubovsky, Yiming Zhong, Amy Lehman, Jeffery Kutok, Jennifer A. Woyach, John C. Byrd, Amy J. Johnson

Article Medicine, Research & Experimental

PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression

Shuai Dong, Bonnie K. Harrington, Eileen Y. Hu, Joseph T. Greene, Amy M. Lehman, Minh Tran, Ronni L. Wasmuth, Meixiao Long, Natarajan Muthusamy, Jennifer R. Brown, Amy J. Johnson, John C. Byrd

JOURNAL OF CLINICAL INVESTIGATION (2019)

Editorial Material Medicine, Research & Experimental

Autologous graft versus myeloma: it's not a myth

Shuai Dong, Irene M. Ghobrial

JOURNAL OF CLINICAL INVESTIGATION (2019)

Article Hematology

Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia

Ishwarya Murali, Siddha Kasar, Aishath Naeem, Svitlana Tyekucheva, Jasneet K. Khalsa, Emily M. Thrash, Gilad Itchaki, Dimitri Livitz, Ignaty Leshchiner, Shuai Dong, Stacey M. Fernandes, Gad Getz, Amy Johnson, Jennifer R. Brown

Summary: Resistance to PI3K delta inhibitors in CLL is associated with baseline activating mutations and activation of the MAPK/ERK pathway, suggesting a rationale for combination therapy with PI3K delta and ERK inhibitors.
暂无数据